US20030049231A1 - Agent for the anti-adhesion of skin pathogenic flora - Google Patents
Agent for the anti-adhesion of skin pathogenic flora Download PDFInfo
- Publication number
- US20030049231A1 US20030049231A1 US10/177,589 US17758902A US2003049231A1 US 20030049231 A1 US20030049231 A1 US 20030049231A1 US 17758902 A US17758902 A US 17758902A US 2003049231 A1 US2003049231 A1 US 2003049231A1
- Authority
- US
- United States
- Prior art keywords
- composition
- bacterial agent
- bacterium
- cfu
- adhesion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
Definitions
- the present invention relates to the use of a bacterial agent selected for its properties of anti-adhesion of skin pathogens, for the preparation of compositions which are for cosmetic, pharmaceutical or veterinary use and which are intended to stabilize and/or regulate the cutaneous ecosystem of mammals, and to the compositions containing such an agent.
- pathogens such as Staphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes, or of certain yeasts
- pathogens such as Staphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes, or of certain yeasts
- pathogens such as Staphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes, or of certain yeasts
- pathogens such as Staphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes, or of certain yeasts
- antibiotics or chemical antibacterial agents are known. They are, for example, compositions based on aldehydes and derivatives.
- French patent application FR 2740039 describes the use of a substance chosen from aldehydes and bifunctional compounds, preferably glutaraldehyde, for inhibiting the attachment of strains of pathogens such as Staphylococcus aureus to keratinocytes and corneocytes.
- hexachlorophene and its derivatives are known as antibacterial substances and are more particularly used against Propionibacterium acnes.
- PCT application WO 97/366603 demonstrates the antifungal properties of a strain of Lactobacillus casei.
- Bacillus can also be used on skin or mucous membranes.
- Bacillus coagulans Bacillus subtilis, Bacillus laterosporus and Bacillus laevolacticus are used in compositions intended to prevent bacterial, viral or fungal infections of skin or of mucous membranes.
- the invention proposes to find a novel bacterial agent capable of controlling and regulating the cutaneous ecosystem in order to improve upon the deficiencies of the prior art.
- the present invention relates to the use of a bacterial agent for preparing a composition which is for cosmetic, pharmaceutical or veterinary use and to the resulting compositions. These compositions are intended to be administered to humans or to animals for the purpose of preventing or treating disorders induced by pathogens of the cutaneous system.
- the bacterial agent is generally an extract of a lactic acid bacterium, or a lactic acid bacterium, and is selected for its properties of adhesion to skin cells as well as for regulation of the attachment of skin pathogens, in particular by inhibiting their adhesion.
- Suitable bacterial agents may be selected from strains of Lactobacillus, Micrococcus or Bifidobacterium, and preferably from the Lactobacillus johnsonii CNCM I-1225, Micrococcus varians CNCM I-1586, Micrococcus varians CNCM I- 1587 or Bifidobacterium lactis ATCC 27536 strains.
- the bacterial strain can be used in a viable, deactivated or semi-active form. It also can be used in the form of a lyophilized powder, which can, e.g., comprise approximately 10 ⁇ 10 8 to 10 ⁇ 10 11 cfu/g.
- compositions of the present invention are intended for cosmetic, pharmaceutical or veterinary use and contain at least one bacterial agent capable of stabilizing and/or of regulating the pathogenic flora of the cutaneous system.
- the bacterial agent is an extract of a bacterium, or a bacterium, selected for its properties of adhesion to skin cells and its anti-adhesive properties with respect to pathogens of the cutaneous system.
- compositions can also be used in ophthalmology or for nasal application. Also, they can in particular be in the form of a cream, lotion, hypoallergenic cleansing bar, shampoo or powder.
- skin cells i.e. keratinocytes
- corneocytes are grouped together under the name “cutaneous system”.
- the present invention provides a bacterial agent selected for its property of adherence to skin cells, and of stabilization and regulation of the pathogenic bacterial flora of the cutaneous system, in particular by inhibiting the adhesion of pathogens such as Staphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes.
- pathogens such as Staphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes.
- pathogens such as Staphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes.
- strains of Lactobacillus, of Micrococcus and of Bifidobacterium have been found to be useful, with a strain of Lactobacillus johnsonii (NCC 533), two strains of Micrococcus varians (NCC 1482, NCC 1520) and a strain of Bifidobacterium lactis (ATCC 27536) being preferred for selection as the agent.
- the strain of Bifidobacterium lactis (ATCC 27536) can be obtained from Hansen (Chr. Hansen A/S, 10-12 Boege Alle, P.O. Box 407, DK-2970 Hoersholm, Denmark).
- CNCM I-1586 NCC 1482
- CNCM I-1587 NCC 1520
- Gram-positive microorganism is permanently immobile.
- Spherical form is in the form of irregularly arranged tetrades.
- the bacteria according to the invention are used for preparing compositions intended for the prophylaxis or the treatment of disorders linked to pathogens of the cutaneous system, such as Staphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes, or yeasts.
- disorders linked to pathogens of the cutaneous system such as Staphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes, or yeasts.
- These skin disorders can be in particular atopic dermatitis (in the remission phases, as a maintenance treatment), acne, candidiases, seborrhoeic dermatitis, pityriasis versicolor, impetigo or eczematous secondary infections.
- the disorders of the cutaneous system may also be linked to therapies with antibiotics or antimycotic agents, to diabetes (candidiases), to a pathology of mucous membranes (vaginal candidiasis), to chronic eczema (homeostasis imbalance), to sensitive skin (premature babies, children) or greasy skin (linked to hormonal dysregulation which may promote the growth of bacteria) or to dandruff.
- therapies with antibiotics or antimycotic agents to diabetes (candidiases), to a pathology of mucous membranes (vaginal candidiasis), to chronic eczema (homeostasis imbalance), to sensitive skin (premature babies, children) or greasy skin (linked to hormonal dysregulation which may promote the growth of bacteria) or to dandruff.
- the bacteria according to the invention can be used in their live or semi-active form, or in a deactivated form.
- the expression “bacterium in a semi-active form” is intended to mean a bacterium with low physiological activity. This activity can be measured by a longer exponential growth phase or generation time, a metabolism which has slowed or an incomplete physiological response to modifications of the environment, for example. In certain extreme cases, the number of bacteria may be decreased since they can no longer withstand the change in the environment.
- Bacterial culture supernatants can also be used successfully in this invention.
- the bacterial agent can be an extract of a bacterium, or a bacterium itself in a viable active form.
- the bacterial agent is then preferably converted into a lyophilized powder, for example, according to the method described in EP 818529.
- the powder typically contains from 10 ⁇ 10 8 to 10 ⁇ 10 11 cfu/g.
- the bacterial agent can be an extract of a bacterium, or the bacterium itself in a semi-active form.
- the partial deactivation of the strains can be carried out in several ways, in particular by:
- freeze drying consisting of cycles of freezing in liquid nitrogen/thawing at 37° C. A decrease of approximately 1 log can then be obtained
- the bacterial agent can then be used in the form of a powder containing at least 10 ⁇ 10 6 cfu/g, and preferably in dry compositions, such as dry shampoos or other powder compositions, which can contain up to 10% of the bacterial extract.
- the bacterial agent can also be an extract of a bacterium, or a bacterium, in a deactivated form.
- the bacterium is preferably inactivated by heat treatment at approximately 90° C. for approximately 2 hours.
- the bacterial agent is in the form of a lyophilized powder containing from 10 ⁇ 10 8 to 10 ⁇ 10 12 cfu/g. It can be used at up to 5%, and from preferably from 0.05 to 3%, in liquid compositions and at up to 10% in pulverulent compositions.
- the present invention also relates to a composition which is for cosmetic, pharmaceutical or veterinary use and which contains a bacterial agent having the properties as described above.
- At least one bacterial strain in viable, semi-active or deactivated form is incorporated into a pharmaceutically or cosmetically acceptable support in an amount which varies as a function of the desired use.
- the bacterial agent can be present at up to approximately 5% with respect to the total weight of the composition and at up to 10% for compositions in the form of a powder, and preferably at between 0.5 to 2%.
- compositions according to the invention can be administered via the topical or ocular route.
- the pharmaceutical compositions based on compounds according to the invention are preferably intended for the treatment of skin and of mucous membranes, and can be in the form of salves, of creams, of milks, of ointments, of powders, of soaked swabs, of solutions, of gels, of sprays, of lotions or of suspensions. They can also be in the form of microspheres or nanospheres, or lipid or polymeric vesicles, or of polymer patches and of hydrogels, which allow controlled release.
- These compositions for administration via the topical route can be either in anhydrous form or aqueous form, depending on the clinical indication.
- the invention relates to a cosmetic composition containing, in a cosmetically acceptable support, at least one bacterial agent as defined above.
- the cosmetic composition can contain the bacterial agent in a proportion of at least 0.001% by weight with respect to the total weight of the composition, and preferably from 0.05 to 3%.
- This cosmetic composition is in particular intended for body and hair hygiene. It can in particular be in the form of a cream, a milk, a lotion, a gel, microspheres or nanospheres, or lipid or polymeric vesicles, a soap or a shampoo.
- the viable or inactivated bacterial agent can be combined with retinoids or corticosteroids, or combined with anti-free radicals, with ⁇ -hydroxy or ⁇ -keto acids or their derivatives, or with ion channel blockers.
- the pharmaceutical and cosmetic compositions according to the invention can also contain inert additives or even pharmacodynamically or cosmetically active additives, or combinations of these additives, and in particular: wetting agents; depigmenting agents such as hydroquinone, azelaic acid, caffeic acid or kojic acid; emollients; moisturizing agents such as glycerol, PEG-400, thiamorpholinone and its derivatives, or urea; anti-seborrhoeic or anti-acne agents, such as S-carboxymethylcysteine, S-benzylcysteamine, their salts and their derivatives, or benzoyl peroxide; antibiotics such as erythromycin and its esters, neomycin, clindamycin and its esters; tetracyclins; antifungal agents such as ketoconazole or 4,5-polymethylene-3-isothiazolinones; agents for promoting the regrowth of
- composition according to the invention can also contain preserving agents such as para-hydroxybenzoic acid esters, stabilizers, moisture regulators, pH regulators, osmotic pressure modifiers, emulsifying agents, UV-A and UV-B screening agents, and antioxidants such as ⁇ -tocopherol, butylhydroxyanisole or butylhydroxytoluene.
- preserving agents such as para-hydroxybenzoic acid esters, stabilizers, moisture regulators, pH regulators, osmotic pressure modifiers, emulsifying agents, UV-A and UV-B screening agents, and antioxidants such as ⁇ -tocopherol, butylhydroxyanisole or butylhydroxytoluene.
- the present invention also relates to a composition which is for veterinary or cosmetic use for animals and which contains at least one bacterial agent as defined above.
- a composition which is for veterinary or cosmetic use for animals and which contains at least one bacterial agent as defined above.
- Such a composition can be in the form of dry or liquid shampoos, powders, foams or lotions, for example. It can contain up to 10% of the bacterial agent.
- composition according to the invention is intended in particular for the therapeutic or prophylactic treatment of healthy, sensitive and/or diseased skin and/or mucous membranes which may exhibit disorders of the cutaneous system, such as in particular:
- infectious complications such as superinfected atopic dermatitis, impetigo-based eczema, ulcers, wounds, bums, superinfected inflammatory acne,
- dermatitises such as impetigo, superficial folliculitis,
- dermatophytoses (Tinea capitis, Tinea corporis, athlete's foot, Hebra's eczema, herpes carcinatus),
- candidiases vaginal, interdigital, linked to professions at risk or to diabetes
- compositions for veterinary use are particularly intended to treat or prevent dysfunctions due to staphylococcal infections (due to Staphylococcus aureus, S. intermedians ), streptococcal infections (due to S. pyogenes ) and mycotic infections (candidoses due to C. albicans and pytirosporoses due to P. canis ).
- the bacterial cultures (1 ml) are incubated in 10 ml of medium (cf. Table 1) overnight.
- the bacteria are precultured until a concentration of 5.0 ⁇ 10 8 to 10 9 cfu/ml is obtained.
- the cfu are standardized by measuring the optical density of each strain (OD at 10 8 cfu/ml: see Table 1).
- the bacterial strains are assayed for their adhesion properties.
- SV40 T-Ag immortalized cell lines DK2-NR and FK2-NR cells as described in EP 780 469 and,
- HPV Human papilloma virus
- E6/E7 and SV40 T-Ag immortalized cell lines DK7-NR cell lines as described in application WO 99/02347.
- the culture medium for the cell lines was as follows: DK7-NR, FK2-NR: NR-2 (Biofluids, Rockville, Md. 20850) (EP 780469). DK2-NR: NR-M (Biofluids, Rockville, Md. 20850).
- the keratinocyte lines are cultured in a proportion of 5 ⁇ 10 5 keratinocytes/cm 2 , seeded in coated 6-well clusters (Becton Dickinson, Lincoln Park, N.J.).
- the coating solution consists of basic medium supplemented with 10 ⁇ g/ml of human fibronectin (Becton Dickinson), 31 ⁇ g/ml of bovine collagen I (Vitrogen, Collagen Corporation, Fremont, Calif.) and 0.1 mg/ml of BSA (Biofluids, Rockville, Md. 20850).
- the cell cultures form a monolayer (confluent).
- the Ca 2+ concentration of the medium is brought to 1.5 mM so as to induce cell differentiation.
- the cells are cultured for 4 days in a high calcium concentration medium, without antibiotics.
- the adhesion assays the cell cultures are washed 3 times with buffer (HBSS, Ca 2+ : 1.0 mM).
- the bacterial strains are labelled overnight by adding 100 ⁇ Ci/10 ml of 2- 3 H-adenine (Amersham, TRK.311) to the culture medium. Aliquot fractions of the bacteria are incubated in a medium without 3 H-adenine. The unlabelled (cold) supernatant is set aside in order to adjust the cfu/ml for the adhesion assays.
- the bacterial suspensions are centrifuged for 10 minutes are 4000 rpm. Before adjusting the optical density (OD), the pellets are washed twice in HBSS. The OD is measured for each strain so as to adjust the final concentrations of bacteria to 10 6 , 10 7 , 10 8 and 10 9 cfu/ml.
- the medium for the adhesion assays is a 1:1 mixture of keratinocyte culture medium and of the unlabelled supernatant of the bacterial medium.
- the bacterial suspensions are incubated on plastic dishes and plastic dishes coated with cells.
- the adhesion index (AI) is calculated as 3 H activity (dpm/well), as % of the total 3 H activity (dpm/ml) of the bacterial suspension.
- the adhesion index of the 13 different bacterial strains is calculated by measuring the 3 H adenine activity of the radiolabelled microorganisms. The results are given in Table 2.
- Immortalized human keratinocytes of the HaCaT line are used (Boukamp P. et al., J. Cell Biol., 106, 761-771, 1988).
- the HaCaT cells are cultured in DMEM medium supplemented with 10% of foetal calf serum, at 37° C. under 5% of CO 2 .
- 6-well clusters (Becton Dickinson) are seeded in a proportion of 10 4 cells/cm 2 . After 4 to 5 days, the cells reach confluence. The adhesion assays are carried out 4 to 5 days after confluence. The monolayers are washed 3 times with PBS before these assays.
- the bacteria are labelled with 2- 3 H-adenine (Amersham, TRK 311), in a proportion of 100 ⁇ Ci/10 ml of broth.
- the suspensions are washed 3 times and then resuspended in PBS.
- the cell density is adjusted in this same buffer.
- the adhesion is defined by the ratio between radioactivity which has adhered and radioactivity which was introduced, multiplied by 100.
- the radiolabelled pathogen and the cold bacterial strain are incubated simultaneously with the monolayer.
- the assays are carried out in triplicate for bacterial agent densities covering 3 logs.
- the in vitro adhesion model is based on the incubation of a radiolabelled and calibrated suspension of a skin pathogenic microorganism ( Staphylococcus aureus ) with a monolayer of immortalized human keratinocytes (HaCaT line) (Boukamp P. et al., J. Cell Biol., 106, 761-771, 1988).
- a skin pathogenic microorganism Staphylococcus aureus
- HaCaT line monolayer of immortalized human keratinocytes
- the inhibitory activity of the bacterial agent ( Lactobacillus johnsonii NCC 533 in a viable or deactivated form) with respect to this adhesion is evaluated in the context of a co-incubation, on the monolayer, of the pathogen and of the compound to be assayed, by measuring the radioactivity retained on the monolayer.
- the HaCaT cells are cultured in DMEM supplemented with 10% of foetal calf serum, at 37° C. under 5% of CO 2 . They are seeded in 6-well clusters in a proportion of 10 4 cells/cm 2 .
- the adhesion assay is carried out 5 days after confluence. The monolayers are washed 3 times with PBS before incubation with the microorganisms.
- Staphylococcus aureus (ATCC 6538) is cultured in TCS medium, in aerobiosis at 35° C.
- Lactobacillus johnsonii NCC 533 is cultured in MRS medium, in anaerobiosis at 37° C.
- the deactivated form of NCC 533 is obtained by lyophilizing a dense suspension of Lactobacilli which has been subjected to several cycles of freezing in liquid nitrogen/thawing at room temperature.
- the preparation assayed corresponds to a biomass of 4.0 ⁇ 10 10 cfu/g.
- mice 15 7- to 8-week-old SKH female mice weighing approximately 30 g were supplied by C. River. 5 mice were used for each group assaying a different topical application.
- Microorganisms A strain of Staphylococcus aureus (named: strain 1) which was isolated from a human skin lesion (leg ulcer) is used. This strain is sensitive to methycilin.
- a suspension of the bacterium is prepared for inoculation in the mice.
- a preculture in the exponential growth phase of strain 1 is prepared on a solid medium (AES, AEB 122 859) at 35° C. for 18 to 24 h.
- the bacterium is resuspended in 10 ml of sterile saline solution, and then recovered after centrifugation at 3000 [lacuna] for 10 min. The supernatant is then removed and the pellet is taken up with 10 ml of saline solution. This procedure is repeated twice.
- An inoculum suspension is prepared by resuspending the washed bacteria in 4 ml of sterile saline solution. The OD at 525 nm is adjusted to approximately 0.14. It contains approximately 10 8 cfu/ml.
- mice The skin of the mice is delipidized on the flanks with 95 [sic] ethanol (Merck). 50 ⁇ l of a suspension containing a 50/50 mixture of the S. aureus inoculum, 10 7 cfu/ml, and of the product to be assayed were slowly applied to the delipidized area (6.25 cm 2 ), using a micropipette. The inoculated sites are protected by occlusion for 1 h under a sterile plastic dressing (Dermafilm 33 ⁇ 15, ref. 38.3015, Vygon laboratory).
- mice 4 hours after application of the suspension, the mice are killed under anaesthesia with forene (Abbott France).
- the inoculated sites are excised as a block (12 mm diameter).
- the skin biopsies removed are ground and homogenized with 2 ml of sterile saline solution, using a Polytron (PT 2100, Bioblock Scientific) (5 rpm, 5 min.).
- a 1 ml sample of the homogenized tissue is added to 9 ml of a sterile saline solution, and 0.1 ml of this mixture is cultured on a staphylococcal medium No. 110 using the 10-fold dilutron method. After 48 hours of incubation at 35° C., the colonies developed are counted and the CFU(colony forming units) are determined.
- NCC 533 at 0.5% and 1% decreases the number of S. aureus bacteria found by approximately 1 log for the inocula at 10 6 cfu/ml and 10 7 cfu/ml. No dose effect is observed, either with the 10 6 cfu/ml inoculum or with the inoculum at 10 7 cfu/ml.
- a body lotion is prepared which has the following composition: 8.0% of mineral oil, 5.0% of isopropyl palmitate, 2.0% of polyglyceryl-3 diisostearate, 4.0% of octyldodecanol, 0.3% of carbomer, 0.2% of sodium cocoylglutamate, 1.2% of 10% sodium hydroxide, a preserving agent, fragrance, 0.5 to 3% of a lyophylisate containing from 10 ⁇ 10 8 to 10 ⁇ 10 12 cfu/g of at least one bacterial strain chosen from Lactobacillus johnsonii (CNCM I-1225), Micrococcus varians (CNCM I-1586 or CNCM I-1587) or Bifidobacterium lactis (ATCC 27536, Hansen) and inactivated by heat treatment at approximately 90° C. for about 2 hours. The mixture is made up to 100% with water.
- the body lotion thus obtained is intended, due to its anti-adhesion properties with respect to pathogens, to stabilize and/or regulate skin pathogenic flora.
- a shampoo is prepared which has the following composition: 7.0% of sodium lauryl sulphate, 2.0% of cocamidopropyl betaine, 2.0% of sodium lauryl sulphonosuccinate, sodium chloride, preserving agent, fragrance and from 0.5 to 3% of a lyophilisate containing from 10 8 to 10 12 cfu/g of at least one bacterial strain chosen from Lactobacillus johnsonii (CNCM I-1225), Micrococcus varians (CNCM I-1586 or CNCM I-1587) or Bifidobacterium lactis ATCC 27536, and inactivated by heat treatment at approximately 90° C. for about 2 hours. The mixture is made up to 100% with water.
- the shampoo thus prepared has properties which regulate scalp pathogenic flora. It is in particular indicated in the treatment of dandruff.
- fatty and aqueous phases are prepared which have the following composition: L. johnsonii (CNCM I-1225) 1% as described in Example 5
- Fatty phase Arachidyl behenyl alcohol/ 3% arachidylglucoside Isohexadecane 7% Sweet almond oil 3% Karite butter 2% B.H.T. 0.05%
- Aqueous phase Water Qs 100% Glycerol 5% Methyl POB 0.1%
- the fatty and aqueous phases are heated to 75° C. Then, emulsification is carried out by adding the aqueous phase to the fatty phase with Rayneri mixing at 1000 rpm. 30 minutes after the emulsification, the mixture is homogenized for 1 minute with a polytron (speed 4-5).
- Example 7 In the same way as in Example 7, a composition is prepared which has the following composition: L. johnsonii (CNCM I-1225) 1% as described in Example 5 Fatty phase: Glyceryl stearate and 5% PEG100 stearate Isohexadecane 8% Karite butter 5% B.H.T. 0.05% DC 1503 1% Aqueous phase: Water Qs 100% Glycerol 3% Carbopol 981 0.2% Lubrajel 5% Phenoxyethanol 1% Sodium hydroxide Qs pH 6
- Example 7 In the same way as in Example 7, a composition is prepared which has the following composition: L. johnsonii (CNCM I-1225) 1% as described in Example 5 Fatty phase: Polyglyceryl-3 diisostearate 5% Cyclomethicone CM5 20% Aqueous phase: Water Qs 100% Glycerol 5% NaCl 0.5% MgSO4 0.5%
- a shampoo for pets is prepared which has the following composition: 5% of sodium lauryl sulphate, 2% of cocamidopropyl betaine, 2% of sodium lauryl sulphonosuccinate, 2% of sodium chloride, 1.5% of PEG-7 glyceryl cocoate, 0.75% of propylene glycol, panthenol, glycerol, disodium phosphate, preserving agent, fragrance and 1% of L. johnsonii (CNCM I-1225) as described in Example 5. The mixture is made up to 100% with water.
- the shampoo thus prepared has properties which regulate the pathogenic flora of the cutaneous system of pets.
Abstract
Bacterial agents for preparing compositions which are for cosmetic, pharmaceutical or veterinary use and which are intended to stabilize and/or regulate the cutaneous ecosystem of mammals. These bacterial agents are extracts of a bacterium, or a bacterium and are selected for their adhesion to skin cells and anti-adhesion to pathogens of the cutaneous system. The invention also relates to compositions containing such agents.
Description
- This is a continuation of the US national stage designation of International Application PCT/EP00/12719 filed Dec. 13, 2000, the entire content of which is expressly incorporated herein by reference thereto.
- The present invention relates to the use of a bacterial agent selected for its properties of anti-adhesion of skin pathogens, for the preparation of compositions which are for cosmetic, pharmaceutical or veterinary use and which are intended to stabilize and/or regulate the cutaneous ecosystem of mammals, and to the compositions containing such an agent.
- The proliferation of pathogens such asStaphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes, or of certain yeasts, can lead to dysregulation of the cutaneous system, or even more serious disorders of skin or of mucous membranes, such as eczema, candidiases, dermatitises, etc.
- Many means of treatment against these pathogenic agents are known. The most conventionally used are antibiotics or chemical antibacterial agents. They are, for example, compositions based on aldehydes and derivatives.
- Thus, the French patent application FR 2740039 describes the use of a substance chosen from aldehydes and bifunctional compounds, preferably glutaraldehyde, for inhibiting the attachment of strains of pathogens such asStaphylococcus aureus to keratinocytes and corneocytes.
- Thus, hexachlorophene and its derivatives are known as antibacterial substances and are more particularly used againstPropionibacterium acnes.
- However, these treatments are in general expensive and harmful to both the health and the environment. Alternatively, nontoxic treatments are now known which consist in using the antifungal, bactericidal or bacteriostatic properties of certain strains of microorganisms.
- Thus, PCT application WO 97/366603 demonstrates the antifungal properties of a strain ofLactobacillus casei.
- Other bacterial agents, such as the Bacillus, can also be used on skin or mucous membranes. Specifically, in application WO 98/47374, strains ofBacillus coagulans, Bacillus subtilis, Bacillus laterosporus and Bacillus laevolacticus are used in compositions intended to prevent bacterial, viral or fungal infections of skin or of mucous membranes.
- The invention proposes to find a novel bacterial agent capable of controlling and regulating the cutaneous ecosystem in order to improve upon the deficiencies of the prior art.
- The present invention relates to the use of a bacterial agent for preparing a composition which is for cosmetic, pharmaceutical or veterinary use and to the resulting compositions. These compositions are intended to be administered to humans or to animals for the purpose of preventing or treating disorders induced by pathogens of the cutaneous system. The bacterial agent is generally an extract of a lactic acid bacterium, or a lactic acid bacterium, and is selected for its properties of adhesion to skin cells as well as for regulation of the attachment of skin pathogens, in particular by inhibiting their adhesion.
- Suitable bacterial agents may be selected from strains of Lactobacillus, Micrococcus or Bifidobacterium, and preferably from theLactobacillus johnsonii CNCM I-1225, Micrococcus varians CNCM I-1586, Micrococcus varians CNCM I-1587 or Bifidobacterium lactis ATCC 27536 strains.
- The bacterial strain can be used in a viable, deactivated or semi-active form. It also can be used in the form of a lyophilized powder, which can, e.g., comprise approximately 10×108 to 10×1011 cfu/g.
- The compositions of the present invention are intended for cosmetic, pharmaceutical or veterinary use and contain at least one bacterial agent capable of stabilizing and/or of regulating the pathogenic flora of the cutaneous system. As noted above, the bacterial agent is an extract of a bacterium, or a bacterium, selected for its properties of adhesion to skin cells and its anti-adhesive properties with respect to pathogens of the cutaneous system.
- These compositions can also be used in ophthalmology or for nasal application. Also, they can in particular be in the form of a cream, lotion, hypoallergenic cleansing bar, shampoo or powder.
- In this invention, skin cells (i.e. keratinocytes) as well as corneocytes are grouped together under the name “cutaneous system”
- The present invention provides a bacterial agent selected for its property of adherence to skin cells, and of stabilization and regulation of the pathogenic bacterial flora of the cutaneous system, in particular by inhibiting the adhesion of pathogens such asStaphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes. For this, many bacterial strains were tested for their properties of attachment to human keratinocytes (cf., Example 1).
- From diverse bacterial strains thus tested, strains of Lactobacillus, of Micrococcus and of Bifidobacterium have been found to be useful, with a strain ofLactobacillus johnsonii (NCC 533), two strains of Micrococcus varians (NCC 1482, NCC 1520) and a strain of Bifidobacterium lactis (ATCC 27536) being preferred for selection as the agent.
- The strain ofLactobacillus johnsonii (NCC 533) and the strains of Micrococcus varians (NCC 1482 and NCC 1520) were deposited, according to the Treaty of Budapest, at the Collection Nationale de Cultures de Microorganismes (CNCM) [National Collection of Microorganism Cultures], Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris Cedex 15, France, respectively on Jun. 30, 1992 under the reference CNCM I-1225 for Lactobacillus johnsonii, and Jun. 07, 1995 under the references and CNCM I-1586 and CNCM I-1587 for Micrococcus varians NCC 1482 and NCC 1520.
- The strain ofBifidobacterium lactis (ATCC 27536) can be obtained from Hansen (Chr. Hansen A/S, 10-12 Boege Alle, P.O. Box 407, DK-2970 Hoersholm, Denmark).
- Details concerning the morphology and the general properties of the strains are given below:
- Morphology
- Non-motile Gram-positive microorganism which does not form spores.
- Fairly short and squat isolated rods.
- Metabolism
- Microaerophilic microorganism with homofermentative metabolism giving rise to the production of L (+) and D (−) lactic acid.
- Other characteristics: Catalase (−), CO2 production (−), arginine hydrolysis (−).
- Fermentation of Sugars:
- Amygdalin (+), arabinose (−), cellobiose (+), esculin (+), fructose (+), galactose (−), glucose (+), lactose (+), maltose (+/−), mannitol (−), mannose (+), melibiose (−), raffinose (+), ribose (−), salicine (+), sucrose (+), trehalose (+).
- Morphology
- Gram-positive microorganism, is permanently immobile.
- Spherical form, is in the form of irregularly arranged tetrades.
- Metabolism
- Aerobic microorganism, catalase (+)
- Other characteristics: yellow colour on BHI medium. The optimum growth temperature of said strains is 25-37° C.
- Fermentation of Sugars
- Fructose (+), glucose (+).
- The bacteria according to the invention are used for preparing compositions intended for the prophylaxis or the treatment of disorders linked to pathogens of the cutaneous system, such asStaphylococcus aureus, Streptococcus pyogenes or Propionibacterium acnes, or yeasts. These skin disorders can be in particular atopic dermatitis (in the remission phases, as a maintenance treatment), acne, candidiases, seborrhoeic dermatitis, pityriasis versicolor, impetigo or eczematous secondary infections.
- The disorders of the cutaneous system may also be linked to therapies with antibiotics or antimycotic agents, to diabetes (candidiases), to a pathology of mucous membranes (vaginal candidiasis), to chronic eczema (homeostasis imbalance), to sensitive skin (premature babies, children) or greasy skin (linked to hormonal dysregulation which may promote the growth of bacteria) or to dandruff.
- The bacteria according to the invention can be used in their live or semi-active form, or in a deactivated form. The expression “bacterium in a semi-active form” is intended to mean a bacterium with low physiological activity. This activity can be measured by a longer exponential growth phase or generation time, a metabolism which has slowed or an incomplete physiological response to modifications of the environment, for example. In certain extreme cases, the number of bacteria may be decreased since they can no longer withstand the change in the environment.
- Bacterial culture supernatants can also be used successfully in this invention.
- According to a first embodiment, the bacterial agent can be an extract of a bacterium, or a bacterium itself in a viable active form. The bacterial agent is then preferably converted into a lyophilized powder, for example, according to the method described in EP 818529. The powder typically contains from 10×108 to 10×1011 cfu/g.
- According to another embodiment, the bacterial agent can be an extract of a bacterium, or the bacterium itself in a semi-active form. The partial deactivation of the strains can be carried out in several ways, in particular by:
- freeze drying, consisting of cycles of freezing in liquid nitrogen/thawing at 37° C. A decrease of approximately 1 log can then be obtained,
- the action of UV rays (15 to 60 minutes at 254 nm, distance 20 cm): decrease of 2 to 3 logs,
- the action of heat (70° C. for 3 hours): decrease of approximately 3 to 4 logs, for example.
- The bacterial agent can then be used in the form of a powder containing at least 10×106 cfu/g, and preferably in dry compositions, such as dry shampoos or other powder compositions, which can contain up to 10% of the bacterial extract.
- Finally, the bacterial agent can also be an extract of a bacterium, or a bacterium, in a deactivated form. The bacterium is preferably inactivated by heat treatment at approximately 90° C. for approximately 2 hours. The bacterial agent is in the form of a lyophilized powder containing from 10×108 to 10×1012 cfu/g. It can be used at up to 5%, and from preferably from 0.05 to 3%, in liquid compositions and at up to 10% in pulverulent compositions.
- The present invention also relates to a composition which is for cosmetic, pharmaceutical or veterinary use and which contains a bacterial agent having the properties as described above.
- In order to prepare such compositions, at least one bacterial strain in viable, semi-active or deactivated form is incorporated into a pharmaceutically or cosmetically acceptable support in an amount which varies as a function of the desired use. The bacterial agent can be present at up to approximately 5% with respect to the total weight of the composition and at up to 10% for compositions in the form of a powder, and preferably at between 0.5 to 2%.
- The compositions according to the invention can be administered via the topical or ocular route.
- Via the topical route, the pharmaceutical compositions based on compounds according to the invention are preferably intended for the treatment of skin and of mucous membranes, and can be in the form of salves, of creams, of milks, of ointments, of powders, of soaked swabs, of solutions, of gels, of sprays, of lotions or of suspensions. They can also be in the form of microspheres or nanospheres, or lipid or polymeric vesicles, or of polymer patches and of hydrogels, which allow controlled release. These compositions for administration via the topical route can be either in anhydrous form or aqueous form, depending on the clinical indication.
- Via the ocular route, they are mainly used as eyewashes.
- In a preferred embodiment, the invention relates to a cosmetic composition containing, in a cosmetically acceptable support, at least one bacterial agent as defined above. The cosmetic composition can contain the bacterial agent in a proportion of at least 0.001% by weight with respect to the total weight of the composition, and preferably from 0.05 to 3%.
- This cosmetic composition is in particular intended for body and hair hygiene. It can in particular be in the form of a cream, a milk, a lotion, a gel, microspheres or nanospheres, or lipid or polymeric vesicles, a soap or a shampoo.
- In the compositions according to the invention, the viable or inactivated bacterial agent can be combined with retinoids or corticosteroids, or combined with anti-free radicals, with α-hydroxy or α-keto acids or their derivatives, or with ion channel blockers.
- The pharmaceutical and cosmetic compositions according to the invention can also contain inert additives or even pharmacodynamically or cosmetically active additives, or combinations of these additives, and in particular: wetting agents; depigmenting agents such as hydroquinone, azelaic acid, caffeic acid or kojic acid; emollients; moisturizing agents such as glycerol, PEG-400, thiamorpholinone and its derivatives, or urea; anti-seborrhoeic or anti-acne agents, such as S-carboxymethylcysteine, S-benzylcysteamine, their salts and their derivatives, or benzoyl peroxide; antibiotics such as erythromycin and its esters, neomycin, clindamycin and its esters; tetracyclins; antifungal agents such as ketoconazole or 4,5-polymethylene-3-isothiazolinones; agents for promoting the regrowth of hair, such as Minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) and its derivatives, Diazoxide (7-chloro-3-methyl-1,2,4-benzothiadiazine 1,1-dioxide) and Phenytoin (5,4-diphenylimidazolidine-2,4-dione) [sic]; nonsteroidal anti-inflammatory agents; carotenoids and, in particular, β-carotene; anti-psoriatic agents such as anthraline and its derivatives; and finally, eicosa-5,8,11,14-tetraynoic acid and eicosa-5,8,11-trynoic acid, their esters and amides.
- The composition according to the invention can also contain preserving agents such as para-hydroxybenzoic acid esters, stabilizers, moisture regulators, pH regulators, osmotic pressure modifiers, emulsifying agents, UV-A and UV-B screening agents, and antioxidants such as α-tocopherol, butylhydroxyanisole or butylhydroxytoluene.
- Finally, the present invention also relates to a composition which is for veterinary or cosmetic use for animals and which contains at least one bacterial agent as defined above. Such a composition can be in the form of dry or liquid shampoos, powders, foams or lotions, for example. It can contain up to 10% of the bacterial agent.
- The composition according to the invention is intended in particular for the therapeutic or prophylactic treatment of healthy, sensitive and/or diseased skin and/or mucous membranes which may exhibit disorders of the cutaneous system, such as in particular:
- infectious complications such as superinfected atopic dermatitis, impetigo-based eczema, ulcers, wounds, bums, superinfected inflammatory acne,
- dermatitises such as impetigo, superficial folliculitis,
- seborrhoeic dermatitises, pityriasis versicolor,
- dermatophytoses (Tinea capitis, Tinea corporis, athlete's foot, Hebra's eczema, herpes carcinatus),
- candidiases (vaginal, interdigital, linked to professions at risk or to diabetes),
- disorders linked to therapies with antibiotics or to antimycotic agents,
- disorders caused by hormonal dysregulation (greasy skin) or to [sic] dandruff,
- sensitive skin (premature babies, children).
- The compositions for veterinary use are particularly intended to treat or prevent dysfunctions due to staphylococcal infections (due toStaphylococcus aureus, S. intermedians), streptococcal infections (due to S. pyogenes) and mycotic infections (candidoses due to C. albicans and pytirosporoses due to P. canis).
- Other characteristics of the present invention will appear in the course of the following descriptions of examples of embodiments, which are provided for the purposes of illustrating the present invention but not to limit it.
- In the context of the present invention, the adhesion of 12 different bacterial strains to skin cells, in particular to HaCat human keratinocytes in culture, is studied. These strains belong to the Lactobacillus, Bifidobacterium, Micrococcus, Staphylococcus, Streptococcus and Propionibacterium genera.
- The bacterial cultures (1 ml) are incubated in 10 ml of medium (cf. Table 1) overnight. For the adhesion assays, the bacteria are precultured until a concentration of 5.0×108 to 109 cfu/ml is obtained. The cfu are standardized by measuring the optical density of each strain (OD at 108 cfu/ml: see Table 1).
- Then, the bacterial strains are assayed for their adhesion properties.
TABLE 1 Bacterial strains and culture conditions OD at NCC Incubation 102 Bacterial strains code Medium T ° C./hour cfu Lactobacillus johnsonii 533 MRS Anaerob. 37° C./ 1.00 La1 48 h Lactobacillus acidophilus 90 MRS Anaerob. 37° C./ 1.00 La10 48 h Bifidobacterium lactis 536 MRS Anaerob. 37° C./ 0.65 ATCC27536 18 h Bifidobacterium longum 585 MRS Aerob. 30° C./18 h 1.32 B28 Micrococcus varians 1482 BHi Aerob. 30° C./18 h 4.85 NCC 1482 Micrococcus varians 1520 BHi Aerob. 30° C./18 h 3.47 NCC 1520 Micrococcus varians 1583 BHi Aerob. 30° C./18 h 4.18 MCV 17 Staphylococcus carnosus 931 BHi Aerob. 30° C./18 h 40.20 STC 21 Staphylococcus 751 BHi Aerob. 30° C./18 h 3.26 piscifermentans STF4 Streptococcus 2019 HJL Aerob. 40° C./18 h 0.37 thermophilus Sfi 16 Propionibacterium 1197 MRS Aerob. 30° C./24 h 0.18 shermanii PP12 Propionibacterium 1116 MRS Aerob. 30° C./24 h 0.25 thoenii PP22 - The adhesion properties of the bacteria were studied on 3 keratinocyte lines:
- SV40 T-Ag immortalized cell lines: DK2-NR and FK2-NR cells as described in EP 780 469 and,
- HPV (Human papilloma virus) E6/E7 and SV40 T-Ag immortalized cell lines: DK7-NR cell lines as described in application WO 99/02347.
- The culture medium for the cell lines was as follows: DK7-NR, FK2-NR: NR-2 (Biofluids, Rockville, Md. 20850) (EP 780469). DK2-NR: NR-M (Biofluids, Rockville, Md. 20850).
- The keratinocyte lines are cultured in a proportion of 5×105 keratinocytes/cm2, seeded in coated 6-well clusters (Becton Dickinson, Lincoln Park, N.J.). The coating solution consists of basic medium supplemented with 10 μg/ml of human fibronectin (Becton Dickinson), 31 μg/ml of bovine collagen I (Vitrogen, Collagen Corporation, Fremont, Calif.) and 0.1 mg/ml of BSA (Biofluids, Rockville, Md. 20850). After 6 to 8 days, the cell cultures form a monolayer (confluent). Next, the Ca2+ concentration of the medium is brought to 1.5 mM so as to induce cell differentiation. The cells are cultured for 4 days in a high calcium concentration medium, without antibiotics. For the adhesion assays, the cell cultures are washed 3 times with buffer (HBSS, Ca2+: 1.0 mM).
- The bacterial strains are labelled overnight by adding 100 μCi/10 ml of 2-3H-adenine (Amersham, TRK.311) to the culture medium. Aliquot fractions of the bacteria are incubated in a medium without 3H-adenine. The unlabelled (cold) supernatant is set aside in order to adjust the cfu/ml for the adhesion assays.
- The bacterial suspensions are centrifuged for 10 minutes are 4000 rpm. Before adjusting the optical density (OD), the pellets are washed twice in HBSS. The OD is measured for each strain so as to adjust the final concentrations of bacteria to 106, 107, 108 and 109 cfu/ml. The medium for the adhesion assays is a 1:1 mixture of keratinocyte culture medium and of the unlabelled supernatant of the bacterial medium.
- In order to analyse the adhesion properties of the bacteria on a substrate without keratinocytes, the bacterial suspensions are incubated on plastic dishes and plastic dishes coated with cells.
- After washing the cultures 3 times with HBSS (Ca2+, 1.0 mM), the bacteria associated with the keratinocytes are lysed in a solution of 1N NaOH for 30 minutes at room temperature. The solution is transferred into scintillation vials with 1 ml of benzethonium hydroxide (Sigma, St. Louis, USA). After 1 h at 60° C., the 3H activity of the label bacteria is measured by liquid scintillation counting (dpm).
- The adhesion index (AI) is calculated as3H activity (dpm/well), as % of the total 3H activity (dpm/ml) of the bacterial suspension.
- (a) Adhesion index (AI)
- The adhesion index of the 13 different bacterial strains is calculated by measuring the3H adenine activity of the radiolabelled microorganisms. The results are given in Table 2.
TABLE 2 Adhesion index of bacterial strains of FK2-NR keratinocytes dpm Adhesion index NCC Code CFU/ml (× 103) =SD (% of total dpm) 533 109 209.6 24.2 1.2 108 175.5 42.5 10.4 107 39.5 1.9 23.3 106 4.7 0.3 27.7 90 109 167.7 19.4 2.8 108 47.7 2.9 7.9 107 8.3 0.5 13.8 106 0.9 0.1 15.5 536 109 413.9 91.7 4.8 108 221.0 31.3 25.5 107 22.3 3.8 25.8 106 2.4 0.3 28.2 585 109 107.7 21.0 1.2 108 19.6 1.5 2.2 107 9.7 1.9 10.8 106 1.3 0.1 14.3 1482 109 6147.2 1292.6 72.4 108 257.7 52.6 30.3 107 10.4 0.8 12.3 106 1.7 0.2 19.7 1520 109 121.2 22.3 1.5 108 40.1 5.7 5.0 107 16.5 5.5 20.7 106 2.3 0.2 29.0 1583 109 41.3 9.7 0.7 108 12.9 1.3 2.2 107 7.5 0.5 12.7 106 1.1 0.1 18.7 751 109 195.5 96.5 2.6 108 24.7 4.9 3.2 107 4.8 0.9 6.4 106 0.6 0.09 8.9 931 109 16.2 2.9 0.5 108 4.6 0.6 1.3 107 1.6 0.1 4.6 106 0.2 0.01 6.7 2019 108 67.5 1.4 1.4 107 10.0 0.4 2.1 106 1.1 0.1 2.4 1197 109 20.2 3.1 0.2 108 3.2 0.2 0.3 107 0.5 0.2 0.4 106 0.1 0.02 0.6 1116 109 34.1 2.0 0.2 108 6.3 0.2 0.4 107 0.7 0.1 0.5 106 0.1 0.01 0.7 - The results show that the highest adhesion indices are obtained for the following strains: aBifidobacterium lactis ATCC 27536, a Lactobacillus johnsonii NCC 533 (CNCM I-1225) strain and the Micrococcus varians NCC 1482 (CNCM I-1586), NCC 1520 (CNCM I-1 587) and NCC 1583 strains.
- In Vitro Assays of the Inhibition of the Adhesion ofStaphylococcus Aureus and Streptococcus pyogenes by Micrococcus varians NCC 1482 or Lactobacillus johnsonii NCC 533.
- The pathogensStaphylococcus aureus and Streptococcus pyogenes are cultured in broth by subculturing from a culture in the exponential growth phase (Table 3 ). An OD/bacterial density correspondence was established for each of the microorganisms assayed, on the basis of cereal dilutions and counting on agar medium.
TABLE 3 Bacterial strain Ref. Medium Culture conditions Staphylococcus aureus ATCC 6538 TCS Aerobiosis, 35° C./ 24 h Streptococcus pyogenes CIP 5641 T BHI Aerobiosis, 35° C./ 24 h - TCS (AES, Combourg, ref. AEB 141502)
- BHI (UNIPATH SA, Dardilly, ref. CM 225)
- Immortalized human keratinocytes of the HaCaT line are used (Boukamp P. et al.,J. Cell Biol., 106, 761-771, 1988). The HaCaT cells are cultured in DMEM medium supplemented with 10% of foetal calf serum, at 37° C. under 5% of CO2.
- 6-well clusters (Becton Dickinson) are seeded in a proportion of 104 cells/cm2. After 4 to 5 days, the cells reach confluence. The adhesion assays are carried out 4 to 5 days after confluence. The monolayers are washed 3 times with PBS before these assays.
- The bacteria are labelled with 2-3H-adenine (Amersham, TRK 311), in a proportion of 100 μCi/10 ml of broth. The suspensions are washed 3 times and then resuspended in PBS. The cell density is adjusted in this same buffer.
- 1 ml of radiolabelled bacterial suspension is incubated for 1 h at 35° C. The monolayer is washed 3 times with PBS buffer and lysed by adding 1N NaOH for 30 minutes at room temperature. The lysate is transferred into a scintillation vial and incubated for 1 h at 60° C. with 1 ml of hyamine hydroxide (Carlo Erba, ref. 464951). The3H activity is counted in a liquid scintillation counter. Each assay is carried out in triplicate. A control with the plastic support is also carried out.
- The adhesion is defined by the ratio between radioactivity which has adhered and radioactivity which was introduced, multiplied by 100.
- After washing and resuspension in PBS, the radiolabelled pathogen and the cold bacterial strain are incubated simultaneously with the monolayer. The assays are carried out in triplicate for bacterial agent densities covering 3 logs.
-
TABLE 4 Microorganism Adhesion (%) 106 cfu/ml 107 cfu/ml 108 cfu/ml Staphylococcus aureus — 5.0 2.5 Streptococcus pyogenes — 35 42.5 NCC 533 4.5 1.7 1.2 NCC 1482 6.5 3.0 0.6 Inhibition (%) 9.0 × 106 9.0 × 107 9.0 × 108 cfu/ml cfu/ml cfu/ml S. aureus 108 cfu/ml + NCC 1482 5 11 66 S. aureus 108 cfu/ml + NCC 533 20 24 34 S. pyogenes 108 cfu/ml + NCC 1482 26 28 40 S. pyogenes 108 cfu/ml + NCC 533 12 19 52 - The results show thatStaphylococcus aureus, Streptococcus pyogenes, Lactobacillus johnsonii NCC 533 and Micrococcus varians NCC 1482 adhere to the keratinocytes in culture. When the density of the bacterial agent increases, the pathogen is increasingly displaced.
- The in vitro adhesion model is based on the incubation of a radiolabelled and calibrated suspension of a skin pathogenic microorganism (Staphylococcus aureus) with a monolayer of immortalized human keratinocytes (HaCaT line) (Boukamp P. et al., J. Cell Biol., 106, 761-771, 1988).
- The inhibitory activity of the bacterial agent (Lactobacillus johnsonii NCC 533 in a viable or deactivated form) with respect to this adhesion is evaluated in the context of a co-incubation, on the monolayer, of the pathogen and of the compound to be assayed, by measuring the radioactivity retained on the monolayer.
- For this, the HaCaT cells are cultured in DMEM supplemented with 10% of foetal calf serum, at 37° C. under 5% of CO2. They are seeded in 6-well clusters in a proportion of 104 cells/cm2. The adhesion assay is carried out 5 days after confluence. The monolayers are washed 3 times with PBS before incubation with the microorganisms.
-
-
- The deactivated form of NCC 533 is obtained by lyophilizing a dense suspension of Lactobacilli which has been subjected to several cycles of freezing in liquid nitrogen/thawing at room temperature. The preparation assayed corresponds to a biomass of 4.0×1010 cfu/g.
- The radiolabelling ofStaphylococcus aureus is obtained by incorporating 100 μCi/10 ml of 3H adenine during 24 h of culturing in TCS broth. The suspension is then centrifuged for 10 minutes at 3000 rpm and washed 3 times in PBS. The cell density is adjusted with PBS buffer to approximately 2.0×108 cfu/ml (OD at 525 nm=0.5). The specific radioactivity is determined by scintillation counting on 100 μl of the suspension.
- 1 ml of radiolabelled suspension ofStaphylococcus aureus and 1 ml of suspension of NCC 533, per well of HaCaT cell culture, are simultaneously added. After 1 h of incubation at 37° C., the monolayers are washed 3 times with PBS buffer and lysed by adding 1 ml of 1N NaOH for 30 minutes at room temperature. The lysate is transferred into scintillation vials and incubated for 1 h at 60° C. with 1 ml of benzethonium hydroxide. After cooling, 10 ml of Hyonic fluor scintillation liquid are added, and the radioactivity is counted on a liquid scintillation counter. The control is obtained by adding 1 ml of radiolabelled suspension of Staphylococcus aureus and 1 ml of PBS buffer, and corresponds to 100% of adhesion.
- The results are given in Table 5.
TABLE 5 Inhibition of the adhesion of Staphylococcus aureus to the HaCaT cells by NCC 533 in its viable form and in its deactivated form. Adhesion (%) Standard deviation Control 100 9 NCC 533 3.0 × 106 cfu/ml 74 19 NCC 533 3.0 × 107 cfu/ml 69 8 NCC 533 3.0 × 108 cfu/ml 34 1 Deactivated NCC 533 3.0 × 106 cfu/ml 27 2 Deactivated NCC 533 3.0 × 107 cfu/ml 12 1 Deactivated NCC 533 3.0 × 108 cfu/ml 6 0 - Animals: 15 7- to 8-week-old SKH female mice weighing approximately 30 g were supplied by C. River. 5 mice were used for each group assaying a different topical application.
- Microorganisms: A strain ofStaphylococcus aureus (named: strain 1) which was isolated from a human skin lesion (leg ulcer) is used. This strain is sensitive to methycilin.
- A suspension of the bacterium is prepared for inoculation in the mice. For this, a preculture in the exponential growth phase of strain 1 is prepared on a solid medium (AES, AEB 122 859) at 35° C. for 18 to 24 h. After incubation, the bacterium is resuspended in 10 ml of sterile saline solution, and then recovered after centrifugation at 3000 [lacuna] for 10 min. The supernatant is then removed and the pellet is taken up with 10 ml of saline solution. This procedure is repeated twice. An inoculum suspension is prepared by resuspending the washed bacteria in 4 ml of sterile saline solution. The OD at 525 nm is adjusted to approximately 0.14. It contains approximately 108 cfu/ml.
- The skin of the mice is delipidized on the flanks with 95 [sic] ethanol (Merck). 50 μl of a suspension containing a 50/50 mixture of theS. aureus inoculum, 107 cfu/ml, and of the product to be assayed were slowly applied to the delipidized area (6.25 cm2), using a micropipette. The inoculated sites are protected by occlusion for 1 h under a sterile plastic dressing (Dermafilm 33×15, ref. 38.3015, Vygon laboratory).
- 4 hours after application of the suspension, the mice are killed under anaesthesia with forene (Abbott France). The inoculated sites are excised as a block (12 mm diameter). The skin biopsies removed are ground and homogenized with 2 ml of sterile saline solution, using a Polytron (PT 2100, Bioblock Scientific) (5 rpm, 5 min.).
- A 1 ml sample of the homogenized tissue is added to 9 ml of a sterile saline solution, and 0.1 ml of this mixture is cultured on a staphylococcal medium No. 110 using the 10-fold dilutron method. After 48 hours of incubation at 35° C., the colonies developed are counted and the CFU(colony forming units) are determined.
- Results: The results are given in Table 6.
TABLE 6 1% NCC 533 assay Log cfu/cm2 S.aureus + PBS 3.4 S.aureus + 1% NCC 533 in PBS 2.6 * S.aureus + 0.045% glutaraldehyde 0.8 * - The presence of NCC 533 at 1% makes it possible to decrease the number of bacteria found by approximately 1 log after 4 hours of contact. The difference appears to be significant with respect to the control (p=0.098).
- In the presence of glutaraldehyde, the decrease in the number of bacteria is even more significant with respect to the control, however it is not out of the question that this activity is due to its antiseptic activity and acts as soon as theS. aureus is added to the mixture; thus, the activity observed after 4 h would not be due to an anti-adhesive effect, but to an antibacterial activity of the product.
- The results are given in Table 7.
TABLE 7 % of Inoculum decrease Significance size cfu/ml Treatment vs. control vs. control 106 cfu/ml 0.5% NCC 533 20.1% P = 0.019 (*) 1% NCC 533 22.6% P = 0.016 (*) 0.045% Glutaraldehyde 87.9% P = 0.0001 (***) 107 cfu/ml 0.5% NCC 533 27.4% P = 0.0015 (*) 1% NCC 533 19.9% P = 0.0004 (***) 0.045% Glutaraldehyde 92.0% P = 0.0004 (***) - The presence of NCC 533 at 0.5% and 1% decreases the number ofS. aureus bacteria found by approximately 1 log for the inocula at 106 cfu/ml and 107 cfu/ml. No dose effect is observed, either with the 106 cfu/ml inoculum or with the inoculum at 107 cfu/ml.
- In the presence of glutaraldehyde at 0.045%, the decrease is much greater with respect to the control; it is approximately 3 logs.
- These results confirm the activity of the deactivated NCC 533 at 0.5% and 1% as an inhibitor of the adhesion ofS. aureus.
- A body lotion is prepared which has the following composition: 8.0% of mineral oil, 5.0% of isopropyl palmitate, 2.0% of polyglyceryl-3 diisostearate, 4.0% of octyldodecanol, 0.3% of carbomer, 0.2% of sodium cocoylglutamate, 1.2% of 10% sodium hydroxide, a preserving agent, fragrance, 0.5 to 3% of a lyophylisate containing from 10×108 to 10×1012 cfu/g of at least one bacterial strain chosen from Lactobacillus johnsonii (CNCM I-1225), Micrococcus varians (CNCM I-1586 or CNCM I-1587) or Bifidobacterium lactis (ATCC 27536, Hansen) and inactivated by heat treatment at approximately 90° C. for about 2 hours. The mixture is made up to 100% with water.
- The body lotion thus obtained is intended, due to its anti-adhesion properties with respect to pathogens, to stabilize and/or regulate skin pathogenic flora.
- A shampoo is prepared which has the following composition: 7.0% of sodium lauryl sulphate, 2.0% of cocamidopropyl betaine, 2.0% of sodium lauryl sulphonosuccinate, sodium chloride, preserving agent, fragrance and from 0.5 to 3% of a lyophilisate containing from 108 to 1012 cfu/g of at least one bacterial strain chosen from Lactobacillus johnsonii (CNCM I-1225), Micrococcus varians (CNCM I-1586 or CNCM I-1587) or Bifidobacterium lactis ATCC 27536, and inactivated by heat treatment at approximately 90° C. for about 2 hours. The mixture is made up to 100% with water.
- The shampoo thus prepared has properties which regulate scalp pathogenic flora. It is in particular indicated in the treatment of dandruff.
- In order to obtain a pharmaceutical composition with properties which regulate skin pathogenic flora, fatty and aqueous phases are prepared which have the following composition:
L. johnsonii (CNCM I-1225) 1% as described in Example 5 Fatty phase: Arachidyl behenyl alcohol/ 3% arachidylglucoside Isohexadecane 7% Sweet almond oil 3% Karite butter 2% B.H.T. 0.05% Propyl POB 0.05% Aqueous phase: Water Qs 100% Glycerol 5% Methyl POB 0.1% - The fatty and aqueous phases are heated to 75° C. Then, emulsification is carried out by adding the aqueous phase to the fatty phase with Rayneri mixing at 1000 rpm. 30 minutes after the emulsification, the mixture is homogenized for 1 minute with a polytron (speed 4-5).
- In the same way as in Example 7, a composition is prepared which has the following composition:
L. johnsonii (CNCM I-1225) 1% as described in Example 5 Fatty phase: Glyceryl stearate and 5% PEG100 stearate Isohexadecane 8% Karite butter 5% B.H.T. 0.05% DC 1503 1% Aqueous phase: Water Qs 100% Glycerol 3% Carbopol 981 0.2% Lubrajel 5% Phenoxyethanol 1% Sodium hydroxide Qs pH 6 - In the same way as in Example 7, a composition is prepared which has the following composition:
L. johnsonii (CNCM I-1225) 1% as described in Example 5 Fatty phase: Polyglyceryl-3 diisostearate 5% Cyclomethicone CM5 20% Aqueous phase: Water Qs 100% Glycerol 5% NaCl 0.5% MgSO4 0.5% - A shampoo for pets is prepared which has the following composition: 5% of sodium lauryl sulphate, 2% of cocamidopropyl betaine, 2% of sodium lauryl sulphonosuccinate, 2% of sodium chloride, 1.5% of PEG-7 glyceryl cocoate, 0.75% of propylene glycol, panthenol, glycerol, disodium phosphate, preserving agent, fragrance and 1% ofL. johnsonii (CNCM I-1225) as described in Example 5. The mixture is made up to 100% with water.
- The shampoo thus prepared has properties which regulate the pathogenic flora of the cutaneous system of pets.
Claims (20)
1. A method of preparing compositions for cosmetic, pharmaceutical or veterinary use and which are intended to be administered to humans or to animals for the therapeutic or prophylactic purpose of stabilizing and/or regulating the pathogenic flora of the cutaneous system, which comprises associating a bacterial agent with the composition, the agent being an extract of a bacterium, or a bacterium, selected for its properties of adhesion to skin cells and its anti-adhesive properties with respect to pathogens of the cutaneous system.
2. The method of claim 1 which further comprises providing the agent in the composition in an amount of at least 10×106 cfu/g.
3. The method of claim 1 , wherein the bacterial agent is selected from the species of Lactobacillus, Micrococcus or Bifidobacterium.
4. The method of claim 1 , wherein the bacterial agent is Lactobacillus johnsonii CNCM I-1225, Micrococcus varians CNCM I-1586, Micrococcus varians CNCM I-1587 or Bifidobacterium lactis ATCC 27536.
5. The method of claim 1 , wherein the bacterium is in a viable, semi-active or deactivated form.
6. The method of claim 5 , wherein the bacterium is deactivated by a heat treatment at 90° C. for 2 hours.
7. The method of claim 5 , wherein the bacterial agent is present in a lyophilized form that contains from 108 to 1011 cfu/g.
8. A composition for cosmetic, pharmaceutical or veterinary use and which contains at least one bacterial agent capable of stabilizing and/or of regulating the pathogenic flora of the cutaneous system, with the bacterial agent being an extract of a bacterium, or a bacterium, and is selected for its properties of adhesion to skin cells and its anti-adhesive properties to pathogens of the cutaneous system.
9. The composition of claim 8 , in which the bacterial agent is a species of Lactobacillus, Micrococcus or Bifidobacterium.
10. The composition of claim 8 , wherein the bacterial agent is Lactobacillus johnsonii CNCM I-1225, Micrococcus varians CNCM I-1586, Micrococcus varians CNCM I-1587 or Bifidobacterium lactis ATCC 27536.
11. The composition of claim 8 , wherein the agent is present in the composition in an amount of at least 10×106 cfu/g.
12. The composition of claim 8 , wherein the bacterium is in a viable, semi-active or deactivated form.
13. The composition of claim 12 , wherein the bacterial agent is present in a lyophilized form that contains from 108 to 1011cfu/g.
14. The composition of claim 12 , in which the bacterium is deactivated by heat treatment at 90° C. for 2 hours.
15. The composition of claim 12 , which contains up to 10% by weight of the bacterial agent with respect to the total weight of the composition.
16. The composition of claim 12 , which contains approximately 0.05 to 5% by weight of the bacterial agent with respect to the total weight of the composition.
17. A method for the treatment or prophylaxis of skin disorders which comprises administering to a subject in need of such treatment or prophylaxis a composition according to claim 8 .
18. The method of claim 17 wherein the skin disorder is one or more of:
infectious complications such as superinfected atopic dermatitis, impetigo-based eczema, ulcers, wounds, bums, superinfected inflammatory acne,
dermatitises such as impetigo, superficial folliculitis,
seborrhoeic dermatitises, pityriasis versicolor,
dermatophytoses,
candidiases,
those linked to therapies with antibiotics or to antimycotic agents,
those caused by hormonal dysregulation, or
dandruff.
19. The method of claim 17 , wherein the composition is applied to sensitive skin or greasy skin.
20. A veterinary composition comprising a composition according to claim 8 , intended for the treatment or for the prevention of dysfunctions linked to staphylococcal, streptococcal and mycotic infections in animals.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/217,930 US8685389B2 (en) | 1999-12-22 | 2005-09-01 | Agent for the anti-adhesion of skin pathogenic flora |
US14/083,098 US9226943B2 (en) | 1999-12-22 | 2013-11-18 | Lactobacillus johnsonii CNCM I-1225 for the anti-adhesion of skin pathogenic flora |
US14/957,889 US20160082052A1 (en) | 1999-12-22 | 2015-12-03 | Agent for the anti-adhesion of skin pathogenic flora |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99204489A EP1110555A1 (en) | 1999-12-22 | 1999-12-22 | Antiadhesive agent for the pathogen flora of the skin |
EP99204489.1 | 1999-12-22 | ||
PCT/EP2000/012719 WO2001045721A1 (en) | 1999-12-22 | 2000-12-13 | Agent which is anti-adhesive in relation to the pathogenic flora of the skin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/012719 Continuation WO2001045721A1 (en) | 1999-12-22 | 2000-12-13 | Agent which is anti-adhesive in relation to the pathogenic flora of the skin |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/217,930 Division US8685389B2 (en) | 1999-12-22 | 2005-09-01 | Agent for the anti-adhesion of skin pathogenic flora |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030049231A1 true US20030049231A1 (en) | 2003-03-13 |
Family
ID=8241061
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/177,589 Abandoned US20030049231A1 (en) | 1999-12-22 | 2002-06-21 | Agent for the anti-adhesion of skin pathogenic flora |
US11/217,930 Expired - Fee Related US8685389B2 (en) | 1999-12-22 | 2005-09-01 | Agent for the anti-adhesion of skin pathogenic flora |
US14/083,098 Expired - Fee Related US9226943B2 (en) | 1999-12-22 | 2013-11-18 | Lactobacillus johnsonii CNCM I-1225 for the anti-adhesion of skin pathogenic flora |
US14/957,889 Abandoned US20160082052A1 (en) | 1999-12-22 | 2015-12-03 | Agent for the anti-adhesion of skin pathogenic flora |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/217,930 Expired - Fee Related US8685389B2 (en) | 1999-12-22 | 2005-09-01 | Agent for the anti-adhesion of skin pathogenic flora |
US14/083,098 Expired - Fee Related US9226943B2 (en) | 1999-12-22 | 2013-11-18 | Lactobacillus johnsonii CNCM I-1225 for the anti-adhesion of skin pathogenic flora |
US14/957,889 Abandoned US20160082052A1 (en) | 1999-12-22 | 2015-12-03 | Agent for the anti-adhesion of skin pathogenic flora |
Country Status (20)
Country | Link |
---|---|
US (4) | US20030049231A1 (en) |
EP (2) | EP1110555A1 (en) |
JP (1) | JP4828759B2 (en) |
KR (1) | KR100797819B1 (en) |
CN (2) | CN101385745B (en) |
AR (1) | AR030925A1 (en) |
AT (1) | ATE471152T1 (en) |
AU (1) | AU3011801A (en) |
BR (1) | BR0016709A (en) |
CA (1) | CA2395419C (en) |
CY (1) | CY1111029T1 (en) |
DE (1) | DE60044566D1 (en) |
DK (1) | DK1244463T3 (en) |
ES (1) | ES2345761T3 (en) |
MX (1) | MXPA02006222A (en) |
NO (1) | NO20022989L (en) |
PL (1) | PL355411A1 (en) |
PT (1) | PT1244463E (en) |
RU (1) | RU2002119396A (en) |
WO (1) | WO2001045721A1 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004023612A1 (en) * | 2004-05-10 | 2005-12-01 | Helmut Meusel | Use of microbial mixed biocoenosis comprising photosynthetic bacteria, actinomycete, lactic acid bacteria, yeast or ferment active fungus, for treating skin inflammations and dermatitis |
WO2006013441A2 (en) * | 2004-07-29 | 2006-02-09 | Proge Farm S.R.L. | Use of probiotic bacteria for the preparation of topical compositions for skin protection |
FR2879452A1 (en) * | 2004-12-21 | 2006-06-23 | Oreal | Use of an extract of a non-fructifying non-photosynthetic filamentous bacteria as an agent modulating the adhesion of cutaneous microorganism on the skin, scalp and/or mucous membranes |
US20060171936A1 (en) * | 2004-10-04 | 2006-08-03 | L'oreal | Cosmetic and/or dermatological composition for sensitive skin |
WO2007039086A1 (en) * | 2005-09-19 | 2007-04-12 | Basf Aktiengesellschaft | Microorganisms inhibiting the formation of foot malodor |
EP1987860A2 (en) | 2007-04-27 | 2008-11-05 | L'oreal | Cosmetic water-soluble film |
US20090068160A1 (en) * | 2007-09-04 | 2009-03-12 | L'oreal | Use of a lysate of bifidobacterium species for treating sensitive skin |
US20090068161A1 (en) * | 2007-09-04 | 2009-03-12 | L'oreal | Use of a combination of hesperidin and of a microorganism for influencing the barrier function of the skin |
US20090098053A1 (en) * | 2002-04-09 | 2009-04-16 | Nestec S.A. | La1 - the genome of a lactobacillus strain |
US20090232785A1 (en) * | 2005-08-01 | 2009-09-17 | L'oreal | Cosmetic and/or dermatological composition for prevention and/or treatment of sensitive or dry skin |
US20100055082A1 (en) * | 2008-09-04 | 2010-03-04 | Jacques Alain Bauer | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
EP2161329A1 (en) * | 2008-09-04 | 2010-03-10 | OM Pharma | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
US20100129324A1 (en) * | 2006-11-06 | 2010-05-27 | Vanessa Crespy | biological effects of compositions comprising rosmarinic acid |
US20100226892A1 (en) * | 2009-03-04 | 2010-09-09 | L'oreal | Use of probiotic microorganisms to limit skin irritation |
US20100278793A1 (en) * | 2008-10-28 | 2010-11-04 | L'oreal | Treatment of greasy skin with a bacterial lystate |
US20100305053A1 (en) * | 2007-08-02 | 2010-12-02 | L'oreal | Use of hesperidin or of a derivative thereof for the prevention and/or treatment of slackened skin |
US20110182861A1 (en) * | 2008-07-29 | 2011-07-28 | Isabelle Castiel | Cosmetic use of microorganisms for the treatment of oily skin |
US20140065209A1 (en) * | 2011-05-03 | 2014-03-06 | Dupont Nutrition Biosciences Aps | Probiotic bacteria for the topical treatment of skin disorders |
AU2010247469B2 (en) * | 2009-05-11 | 2014-12-18 | Société des Produits Nestlé S.A. | Lactobacillus johnsonii La1 NCC533 (CNCM I-1225) and immune disorders |
US20150093462A1 (en) * | 2013-09-30 | 2015-04-02 | Elc Management Llc | Watery Lotion Skin Care Compositions And Methods |
US20160317432A1 (en) * | 2015-04-28 | 2016-11-03 | The Procter & Gamble Company | Compositions And Methods For Improving Skin Health |
US20180140540A1 (en) * | 2016-11-23 | 2018-05-24 | Gojo Industries, Inc. | Topical cleansing composition with prebiotic/probiotic additive |
WO2019226002A1 (en) * | 2018-05-23 | 2019-11-28 | 주식회사 고바이오랩 | Lactobacillus crispatus kbl693 strain and use thereof |
US11154731B2 (en) | 2007-09-04 | 2021-10-26 | L'oreal | Cosmetic use of Bifidobacterium species lysate for the treatment of dryness |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0124580D0 (en) * | 2001-10-12 | 2001-12-05 | Univ Reading | New composition |
UA77066C2 (en) * | 2002-02-21 | 2006-10-16 | Nestle Sa | Orally administrable composition for the photoprotection of the skin |
FR2844198A1 (en) * | 2002-09-06 | 2004-03-12 | Oreal | Restricting complement activating side-effects in skin, mucosa and/or scalp, e.g. for combating irritation due to other active agents, using activator of production of protectin or its precursor |
JP2008503563A (en) * | 2004-06-23 | 2008-02-07 | ロレアル | Methods and compositions useful for the prevention and / or treatment of sensitive and / or dry skin |
FR2872047B1 (en) * | 2004-06-23 | 2007-06-15 | Oreal | COMPOSITION FOR SENSITIVE SKINS COMBINING MINERAL AND PROBIOTIC CATION (S) |
EP1642570A1 (en) | 2004-10-04 | 2006-04-05 | L'oreal | Cosmetic or dermatologic composition against dry and/or sensitive skin |
EP1731137A1 (en) * | 2005-06-08 | 2006-12-13 | Nestec S.A. | Cosmetic or dermatologic composition against dry and/or sensitive skin |
JP2005139198A (en) * | 2004-12-11 | 2005-06-02 | Koichi Takezaki | Life-related goods with added odor suppression effect |
JP4726109B2 (en) * | 2005-02-10 | 2011-07-20 | 昭和電工株式会社 | External preparation for skin, method for preventing adhesion and proliferation of harmful skin microorganisms using the same |
FR2930443B1 (en) | 2008-04-29 | 2010-06-25 | Oreal | EXTEMPORANE CARE PRODUCT BASED ON MICROORGANISM LYOPHILISATE AND SURFACTANT (S) HLB UP TO 12 |
FR2938429B1 (en) * | 2008-11-19 | 2012-05-18 | Oreal | COSMETIC USE OF MICROORGANISM (S) FOR THE TREATMENT OF SKIN LEATHER DISORDERS |
FR2945944B1 (en) * | 2009-06-02 | 2011-07-15 | Oreal | COSMETIC PROCESS FOR TREATING FILM STATES COMPRISING THE ADMINISTRATION OF A PROBIOTIC MICROORGANISM AND ANTIPELLICULAR ACTIVE INGREDIENT |
CN102131495B (en) * | 2008-07-29 | 2017-07-04 | 欧莱雅 | Microorganism is used to treat the cosmetic applications of scalp illness |
FR2937536B1 (en) * | 2008-10-28 | 2016-07-01 | Oreal | COSMETIC USE OF A SPECIFIC BIFIDOBACTERIUM LYSATE FOR THE TREATMENT OF FAT SKIN LEATHER |
EP2251022A1 (en) * | 2009-05-11 | 2010-11-17 | Nestec S.A. | Non-replicating micro-organisms and their immune boosting effect |
EP2251020A1 (en) * | 2009-05-11 | 2010-11-17 | Nestec S.A. | Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles |
GB2472790A (en) * | 2009-08-18 | 2011-02-23 | Laurence Christian Hayes | Dermatological preparations comprising microbes. |
EP2364712B1 (en) * | 2010-03-11 | 2013-03-06 | Kloarys Investment Ltd | Topical cosmetic or pharmaceutical composition comprising probiotic lactobacillus strains and use of same |
FR2959128B1 (en) * | 2010-04-23 | 2012-07-13 | Oreal | COSMETIC USE OF A SPECIFIC BIFIDOBACTERIUM LYSATE FOR THE TREATMENT OF BODY ODORS |
DE102011009798B4 (en) * | 2011-01-31 | 2015-03-05 | Merz Pharma Gmbh & Co. Kgaa | Balneological lipid-containing probiotic preparations for cosmetic / dermatological / medical applications |
US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US11191665B2 (en) | 2011-02-04 | 2021-12-07 | Joseph E. Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US10940169B2 (en) | 2015-11-30 | 2021-03-09 | Joseph E. Kovarik | Method for reducing the likelihood of developing cancer in an individual human being |
US10835560B2 (en) | 2013-12-20 | 2020-11-17 | Joseph E. Kovarik | Reducing the likelihood of skin cancer in an individual human being |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US10583033B2 (en) | 2011-02-04 | 2020-03-10 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US10010568B2 (en) | 2011-02-04 | 2018-07-03 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a spirochetes infection in a human being |
US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
US10085938B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for preventing sore throat in humans |
US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
US10111913B2 (en) | 2011-02-04 | 2018-10-30 | Joseph E. Kovarik | Method of reducing the likelihood of skin cancer in an individual human being |
US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
JP6267633B2 (en) * | 2011-05-06 | 2018-01-24 | オルガノバランス メディカル アーゲー | Novel lactic acid bacteria and composition containing the same |
FR2998174B1 (en) * | 2012-11-21 | 2016-06-10 | Greentech | PROCESS FOR PREPARING A COSMETIC OR DERMATOLOGICAL ACTIVE INGREDIENT |
FR2999931A1 (en) | 2012-12-21 | 2014-06-27 | Oreal | USE OF PROBIOTIC MICROORGANISMS AS AN AGENT PROMOTING MELANIN SYNTHESIS |
FR2999932B1 (en) | 2012-12-21 | 2020-01-31 | Société des Produits Nestlé S.A. | USE OF PROBIOTIC MICROORGANISMS AS A MELANIN SYNTHESIS AGENT |
US11642382B2 (en) | 2013-12-20 | 2023-05-09 | Seed Health, Inc. | Method for treating an individual suffering from bladder cancer |
US11026982B2 (en) | 2015-11-30 | 2021-06-08 | Joseph E. Kovarik | Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11529379B2 (en) | 2013-12-20 | 2022-12-20 | Seed Health, Inc. | Method and system for reducing the likelihood of developing colorectal cancer in an individual human being |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11672835B2 (en) | 2013-12-20 | 2023-06-13 | Seed Health, Inc. | Method for treating individuals having cancer and who are receiving cancer immunotherapy |
US11213552B2 (en) | 2015-11-30 | 2022-01-04 | Joseph E. Kovarik | Method for treating an individual suffering from a chronic infectious disease and cancer |
CA2950945A1 (en) | 2014-06-17 | 2015-12-23 | Xycrobe Therapeutics, Inc. | Genetically modified bacteria and methods for genetic modification of bacteria |
EP3359174A1 (en) * | 2015-10-07 | 2018-08-15 | Galderma Research & Development | Composition containing lactic acid bacteria and its use to treat atopic dermatitis |
US10419395B2 (en) * | 2015-10-23 | 2019-09-17 | International Business Machines Corporation | Routing packets in a data center network |
US10675347B2 (en) | 2015-11-30 | 2020-06-09 | Joseph E. Kovarik | Method and system for protecting honey bees from fipronil pesticides |
US10933128B2 (en) | 2015-11-30 | 2021-03-02 | Joseph E. Kovarik | Method and system for protecting honey bees from pesticides |
US10568916B2 (en) | 2015-11-30 | 2020-02-25 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
US11529412B2 (en) | 2015-11-30 | 2022-12-20 | Seed Health, Inc. | Method and system for protecting honey bees from pesticides |
US10086024B2 (en) | 2015-11-30 | 2018-10-02 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
WO2017147507A1 (en) | 2016-02-24 | 2017-08-31 | Xycrobe Therapeutics, Inc. | Skin probiotic formulation |
RU2652277C1 (en) * | 2017-04-13 | 2018-04-25 | Артем Михайлович Гурьев | Microcapsules, containing living microorganisms, and their application |
JP7208894B2 (en) * | 2017-05-23 | 2023-01-19 | 森永乳業株式会社 | Cosmetics and skin protection agents containing lactic acid bacteria |
EP3666341B1 (en) * | 2018-12-14 | 2022-03-23 | DWI - Leibniz-Institut für Interaktive Materialien e.V. | Topical formulation in form of a patch, a bandage or a plaster comprising probiotic bacteria, and use thereof in a method for treating or preventing skin disorders |
US20200368146A1 (en) * | 2019-05-22 | 2020-11-26 | Mary Ahern | Method of cosmetic preservation |
CN111534447B (en) * | 2019-12-11 | 2022-05-24 | 沈阳博阳饲料股份有限公司 | Lactobacillus johnsonii and application thereof |
FR3124077A1 (en) * | 2021-06-22 | 2022-12-23 | Nanyang Technological University | Use of a short chain fatty acid as an antidandruff agent |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5324515A (en) * | 1991-10-22 | 1994-06-28 | Pacific Corporation | Cosmetic material obtained from a lactic acid fermentation broth |
US5422370A (en) * | 1986-12-23 | 1995-06-06 | Tristrata Inc | Method of using 2-hydroxypropanoic acid (lactic acid) for the treatment of wrinkles |
US5578302A (en) * | 1992-07-06 | 1996-11-26 | Nestec S.A. | Treatment of stomach ulcers |
US5603930A (en) * | 1992-07-06 | 1997-02-18 | Nestec S.A. | Lactobacillus johnsonii CNCM I-1225 |
US5614209A (en) * | 1993-12-03 | 1997-03-25 | Lafor Laboratories Limited | Micro-encapsulated lactobacilli for medical applications |
US5981261A (en) * | 1995-08-07 | 1999-11-09 | Nestec, S.A. | Micrococcus varians strains for producing bactericide compositions |
US6270811B1 (en) * | 1996-11-26 | 2001-08-07 | 1 Fois 1 Jour Concept | Pharmaceutical, cosmetic composition with base of microbial culture mixed with an essential oil and an acid |
US6645506B1 (en) * | 1997-04-18 | 2003-11-11 | Ganeden Biotech, Inc. | Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3024318A1 (en) * | 1980-06-27 | 1982-01-28 | Chemisches Laboratorium Dr. Karl Richter GmbH, 1000 Berlin | COSMETIC AGENTS |
JPS5920220A (en) * | 1982-07-23 | 1984-02-01 | Yakult Honsha Co Ltd | Remedy for wound surface of damaged skin |
JPH0818995B2 (en) * | 1987-01-21 | 1996-02-28 | 株式会社アドバンス | Antibacterial agent for skin |
JPH0517363A (en) * | 1991-07-11 | 1993-01-26 | Yakult Honsha Co Ltd | Antiphlogistic agent and cosmetic containing the same |
CN1110147A (en) * | 1994-04-09 | 1995-10-18 | 山田武敏 | Antiallergic composition |
AU2631695A (en) * | 1994-06-17 | 1996-01-15 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Method for introduction of genetic material into microorganisms and transformants obtained therewith |
US5656268A (en) * | 1995-04-21 | 1997-08-12 | Sorodsky; Michael | Biological product |
JPH092959A (en) * | 1995-06-16 | 1997-01-07 | Yakult Honsha Co Ltd | Immuno-globulin e antibody production suppressant and antiallergic agent |
JPH09263539A (en) * | 1996-03-29 | 1997-10-07 | Nichinichi Seiyaku Kk | Therapeutic agent for dermatopathy having antifungal action |
AUPN907296A0 (en) * | 1996-04-02 | 1996-04-26 | Commonwealth Scientific And Industrial Research Organisation | Biocontrol agents for use in treatment of opportunistic infections |
PT818529E (en) * | 1996-07-09 | 2005-09-30 | Nestle Sa | POWDER DRYING PROCESS |
ATE493139T1 (en) * | 1997-04-18 | 2011-01-15 | Ganeden Biotech Inc | SURFACE USE OF PROBIOTIC BACILLUS SPORES TO PREVENT OR CONTROL MICROBIAL INFECTIONS |
EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
WO1999017788A1 (en) * | 1997-10-06 | 1999-04-15 | Abbott Laboratories | Composition of treatment of candidiasis |
EP1364586A1 (en) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotics and oral tolerance |
-
1999
- 1999-12-22 EP EP99204489A patent/EP1110555A1/en not_active Withdrawn
-
2000
- 2000-12-13 PL PL00355411A patent/PL355411A1/en not_active Application Discontinuation
- 2000-12-13 CN CN2008102106537A patent/CN101385745B/en not_active Expired - Fee Related
- 2000-12-13 KR KR1020027008084A patent/KR100797819B1/en not_active IP Right Cessation
- 2000-12-13 DE DE60044566T patent/DE60044566D1/en not_active Expired - Lifetime
- 2000-12-13 AT AT00990751T patent/ATE471152T1/en active
- 2000-12-13 RU RU2002119396/15A patent/RU2002119396A/en unknown
- 2000-12-13 AU AU30118/01A patent/AU3011801A/en not_active Abandoned
- 2000-12-13 CN CN008191484A patent/CN1434716B/en not_active Expired - Fee Related
- 2000-12-13 EP EP00990751A patent/EP1244463B1/en not_active Expired - Lifetime
- 2000-12-13 BR BR0016709-6A patent/BR0016709A/en not_active Application Discontinuation
- 2000-12-13 JP JP2001546660A patent/JP4828759B2/en not_active Expired - Fee Related
- 2000-12-13 ES ES00990751T patent/ES2345761T3/en not_active Expired - Lifetime
- 2000-12-13 PT PT00990751T patent/PT1244463E/en unknown
- 2000-12-13 MX MXPA02006222A patent/MXPA02006222A/en unknown
- 2000-12-13 CA CA2395419A patent/CA2395419C/en not_active Expired - Lifetime
- 2000-12-13 DK DK00990751.0T patent/DK1244463T3/en active
- 2000-12-13 WO PCT/EP2000/012719 patent/WO2001045721A1/en not_active Application Discontinuation
- 2000-12-22 AR ARP000106915A patent/AR030925A1/en unknown
-
2002
- 2002-06-20 NO NO20022989A patent/NO20022989L/en not_active Application Discontinuation
- 2002-06-21 US US10/177,589 patent/US20030049231A1/en not_active Abandoned
-
2005
- 2005-09-01 US US11/217,930 patent/US8685389B2/en not_active Expired - Fee Related
-
2010
- 2010-09-08 CY CY20101100817T patent/CY1111029T1/en unknown
-
2013
- 2013-11-18 US US14/083,098 patent/US9226943B2/en not_active Expired - Fee Related
-
2015
- 2015-12-03 US US14/957,889 patent/US20160082052A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5422370A (en) * | 1986-12-23 | 1995-06-06 | Tristrata Inc | Method of using 2-hydroxypropanoic acid (lactic acid) for the treatment of wrinkles |
US5422370B1 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of using 2-hydroxypropanoic acid (lactic acid) for the treatment of wrinkles |
US5324515A (en) * | 1991-10-22 | 1994-06-28 | Pacific Corporation | Cosmetic material obtained from a lactic acid fermentation broth |
US5578302A (en) * | 1992-07-06 | 1996-11-26 | Nestec S.A. | Treatment of stomach ulcers |
US5603930A (en) * | 1992-07-06 | 1997-02-18 | Nestec S.A. | Lactobacillus johnsonii CNCM I-1225 |
US5635202A (en) * | 1993-12-03 | 1997-06-03 | Lafor Laboratories Limited | Micro-encapsulated lactobacilli for medical applications |
US5633012A (en) * | 1993-12-03 | 1997-05-27 | Lafor Laboratories Limited | Micro-encapsulated lactobacilli for medical applications |
US5614209A (en) * | 1993-12-03 | 1997-03-25 | Lafor Laboratories Limited | Micro-encapsulated lactobacilli for medical applications |
US5733568A (en) * | 1993-12-03 | 1998-03-31 | Lafor Laboratories Limited | Micro-encapsulated lactobacilli for medical applications |
US5614209B1 (en) * | 1993-12-03 | 1998-08-04 | Lafor Lab Ltd | Micro-encapsulated lactobacilli for medical applications |
US5981261A (en) * | 1995-08-07 | 1999-11-09 | Nestec, S.A. | Micrococcus varians strains for producing bactericide compositions |
US6270811B1 (en) * | 1996-11-26 | 2001-08-07 | 1 Fois 1 Jour Concept | Pharmaceutical, cosmetic composition with base of microbial culture mixed with an essential oil and an acid |
US6645506B1 (en) * | 1997-04-18 | 2003-11-11 | Ganeden Biotech, Inc. | Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090098053A1 (en) * | 2002-04-09 | 2009-04-16 | Nestec S.A. | La1 - the genome of a lactobacillus strain |
US7875421B2 (en) * | 2002-04-09 | 2011-01-25 | Nestec S.A. | La1—the genome of a lactobacillus strain |
DE102004023612A1 (en) * | 2004-05-10 | 2005-12-01 | Helmut Meusel | Use of microbial mixed biocoenosis comprising photosynthetic bacteria, actinomycete, lactic acid bacteria, yeast or ferment active fungus, for treating skin inflammations and dermatitis |
WO2006013441A2 (en) * | 2004-07-29 | 2006-02-09 | Proge Farm S.R.L. | Use of probiotic bacteria for the preparation of topical compositions for skin protection |
WO2006013441A3 (en) * | 2004-07-29 | 2006-04-06 | Proge Farm Srl | Use of probiotic bacteria for the preparation of topical compositions for skin protection |
US20060171936A1 (en) * | 2004-10-04 | 2006-08-03 | L'oreal | Cosmetic and/or dermatological composition for sensitive skin |
FR2879452A1 (en) * | 2004-12-21 | 2006-06-23 | Oreal | Use of an extract of a non-fructifying non-photosynthetic filamentous bacteria as an agent modulating the adhesion of cutaneous microorganism on the skin, scalp and/or mucous membranes |
US20090232785A1 (en) * | 2005-08-01 | 2009-09-17 | L'oreal | Cosmetic and/or dermatological composition for prevention and/or treatment of sensitive or dry skin |
WO2007039086A1 (en) * | 2005-09-19 | 2007-04-12 | Basf Aktiengesellschaft | Microorganisms inhibiting the formation of foot malodor |
US20090130073A1 (en) * | 2005-09-19 | 2009-05-21 | Basf Se | Microorganisms Inhibiting the Formation of Foot Malodor |
US9314490B2 (en) | 2006-11-06 | 2016-04-19 | Nestec S.A. | Biological effects of compositions of rosmarinic acid |
US20100129324A1 (en) * | 2006-11-06 | 2010-05-27 | Vanessa Crespy | biological effects of compositions comprising rosmarinic acid |
US8932579B2 (en) * | 2006-11-06 | 2015-01-13 | Nestec S.A. | Biological effects of compositions comprising rosmarinic acid |
EP1987860A2 (en) | 2007-04-27 | 2008-11-05 | L'oreal | Cosmetic water-soluble film |
US20090022700A1 (en) * | 2007-04-27 | 2009-01-22 | L'oreal | Cosmetic water-soluble film |
US20100305053A1 (en) * | 2007-08-02 | 2010-12-02 | L'oreal | Use of hesperidin or of a derivative thereof for the prevention and/or treatment of slackened skin |
US10238897B2 (en) * | 2007-09-04 | 2019-03-26 | L'oreal | Use of a lysate of bifidobacterium species for treating sensitive skin |
US20090068160A1 (en) * | 2007-09-04 | 2009-03-12 | L'oreal | Use of a lysate of bifidobacterium species for treating sensitive skin |
US11154731B2 (en) | 2007-09-04 | 2021-10-26 | L'oreal | Cosmetic use of Bifidobacterium species lysate for the treatment of dryness |
US20090068161A1 (en) * | 2007-09-04 | 2009-03-12 | L'oreal | Use of a combination of hesperidin and of a microorganism for influencing the barrier function of the skin |
US8951775B2 (en) | 2008-07-29 | 2015-02-10 | L'oreal | Cosmetic use of microorganisms for the treatment of oily skin |
US20110182861A1 (en) * | 2008-07-29 | 2011-07-28 | Isabelle Castiel | Cosmetic use of microorganisms for the treatment of oily skin |
EP2540818A1 (en) * | 2008-09-04 | 2013-01-02 | OM Pharma | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
EP2161329A1 (en) * | 2008-09-04 | 2010-03-10 | OM Pharma | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
US20100055082A1 (en) * | 2008-09-04 | 2010-03-04 | Jacques Alain Bauer | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
US20100278793A1 (en) * | 2008-10-28 | 2010-11-04 | L'oreal | Treatment of greasy skin with a bacterial lystate |
US9782611B2 (en) * | 2008-10-28 | 2017-10-10 | L'oreal | Treatment of greasy skin with a bacterial lystate |
US8481299B2 (en) | 2009-03-04 | 2013-07-09 | L'oreal | Use of probiotic microorganisms to limit skin irritation |
US20100226892A1 (en) * | 2009-03-04 | 2010-09-09 | L'oreal | Use of probiotic microorganisms to limit skin irritation |
AU2010247469B2 (en) * | 2009-05-11 | 2014-12-18 | Société des Produits Nestlé S.A. | Lactobacillus johnsonii La1 NCC533 (CNCM I-1225) and immune disorders |
US10576110B2 (en) | 2009-05-11 | 2020-03-03 | Societe Des Produits Nestle S.A. | Lactobacillus johnsonii La1 NCC533 (CNCM I-1225) and immune disorders |
TWI489988B (en) * | 2009-05-11 | 2015-07-01 | 耐斯泰克公司 | Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders |
US20140065209A1 (en) * | 2011-05-03 | 2014-03-06 | Dupont Nutrition Biosciences Aps | Probiotic bacteria for the topical treatment of skin disorders |
US20160008412A1 (en) * | 2011-05-03 | 2016-01-14 | Dupont Nutrition Biosciences Aps | Probiotic bacteria for the topical treatment of skin disorders |
US10555977B2 (en) | 2011-05-03 | 2020-02-11 | Dupont Nutrition Biosciences Aps | Probiotic bacteria for the topical treatment of skin disorders |
US20150093462A1 (en) * | 2013-09-30 | 2015-04-02 | Elc Management Llc | Watery Lotion Skin Care Compositions And Methods |
US9913800B2 (en) * | 2015-04-28 | 2018-03-13 | The Procter & Gamble Company | Compositions and methods for improving skin health |
WO2016176380A1 (en) * | 2015-04-28 | 2016-11-03 | The Procter & Gamble Company | Compositions comprising whole, non-viable micrococcus for improving skin health |
US20160317432A1 (en) * | 2015-04-28 | 2016-11-03 | The Procter & Gamble Company | Compositions And Methods For Improving Skin Health |
US20180140540A1 (en) * | 2016-11-23 | 2018-05-24 | Gojo Industries, Inc. | Topical cleansing composition with prebiotic/probiotic additive |
WO2019226002A1 (en) * | 2018-05-23 | 2019-11-28 | 주식회사 고바이오랩 | Lactobacillus crispatus kbl693 strain and use thereof |
US11141444B2 (en) | 2018-05-23 | 2021-10-12 | Ko Biolabs, Inc. | Lactobacillus crispatus KBL693 strain and use thereof |
US11633439B2 (en) | 2018-05-23 | 2023-04-25 | Kobiolabs, Inc. | Lactobacillus crispatus KBL693 strain and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101385745A (en) | 2009-03-18 |
MXPA02006222A (en) | 2002-12-05 |
CN101385745B (en) | 2011-05-18 |
CY1111029T1 (en) | 2015-06-11 |
US20160082052A1 (en) | 2016-03-24 |
WO2001045721A1 (en) | 2001-06-28 |
NO20022989D0 (en) | 2002-06-20 |
CN1434716A (en) | 2003-08-06 |
EP1244463B1 (en) | 2010-06-16 |
JP4828759B2 (en) | 2011-11-30 |
KR100797819B1 (en) | 2008-01-24 |
AR030925A1 (en) | 2003-09-03 |
AU3011801A (en) | 2001-07-03 |
CA2395419C (en) | 2010-07-06 |
DE60044566D1 (en) | 2010-07-29 |
US20060002910A1 (en) | 2006-01-05 |
CA2395419A1 (en) | 2001-06-28 |
PL355411A1 (en) | 2004-04-19 |
US20140079677A1 (en) | 2014-03-20 |
EP1110555A1 (en) | 2001-06-27 |
NO20022989L (en) | 2002-08-16 |
CN1434716B (en) | 2012-03-28 |
ES2345761T3 (en) | 2010-10-01 |
DK1244463T3 (en) | 2010-09-20 |
BR0016709A (en) | 2002-09-03 |
PT1244463E (en) | 2010-09-07 |
ATE471152T1 (en) | 2010-07-15 |
RU2002119396A (en) | 2004-02-27 |
KR20020068382A (en) | 2002-08-27 |
JP2003518070A (en) | 2003-06-03 |
EP1244463A1 (en) | 2002-10-02 |
US8685389B2 (en) | 2014-04-01 |
US9226943B2 (en) | 2016-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9226943B2 (en) | Lactobacillus johnsonii CNCM I-1225 for the anti-adhesion of skin pathogenic flora | |
AU2012203217B2 (en) | Methods and means for protecting the skin against pathogenic microorganisms | |
US8481299B2 (en) | Use of probiotic microorganisms to limit skin irritation | |
US8283136B2 (en) | Skin treatment compositions | |
US20090035294A1 (en) | Lipopolysaccharide fractions of vitreoscilla filiformis useful for stimulating the synthesis of anti-microbial peptides of the skin | |
AU2017202471B2 (en) | Peptide for use in the treatment of skin conditions | |
KR102441226B1 (en) | A composition for skin microbiome comprising mixed probiotics fermentation product and cosmetic composition comprising the same | |
CA2415918C (en) | Agent for inhibiting adhesion of the pathogenic flora of the skin | |
US10953051B2 (en) | Methods and means for protecting the skin against pathogenic microorganisms | |
KR20240008176A (en) | Functional cosmetic composition comprising an extract of a novel Lactobacillus lactic acid bacteria HK9 complex ferment extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NESTEC S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAUR, MARKUS;ZINK, RALF;AUZANNEAU, ISABELLE;AND OTHERS;REEL/FRAME:013646/0178;SIGNING DATES FROM 20020702 TO 20021008 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |